India’s first wave of generic semaglutide approvals is underway, as multiple domestic drugmakers secure clearances for obesity and metabolic treatments, setting the stage for lower-cost alternatives when patent protections expire, reported The Economic Times.
Over the past few months, the Central Drugs Standard Control Organisation has cleared a range of semaglutide formulations for chronic weight management and type 2 diabetes, with key approvals dated January 16, 2026, and earlier clearances between September and December 2025.
Companies receiving approvals include Sun Pharmaceutical, Zydus Lifesciences, Alkem Laboratories and Dr Reddy’s Laboratories, alongside the drug original developer Novo Nordisk.
On Friday, Sun Pharma said it had received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management, marking one of the first formal announcements tied to the latest regulatory clearances.
Sun Pharma said it will launch the product under the brand name Noveltreat after the expiry of semaglutide’s patent in India.
Source : firstwordpharma
